Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
An update from Anatara Lifesciences Ltd ( (AU:ANR) ) is now available.
Anatara Lifesciences Ltd announced a change in the director’s interest, with Dr. David Brookes acquiring additional shares through entities Tarandi and Dahlbrook Family Trust. This acquisition, valued at $40,000, reflects a strategic move that could influence the company’s market positioning and stakeholder confidence.
More about Anatara Lifesciences Ltd
Anatara Lifesciences Ltd operates in the biotechnology industry, focusing on developing therapeutic solutions for gastrointestinal diseases. The company is known for its innovative approach to addressing unmet medical needs in both human and animal health markets.
Average Trading Volume: 3,342,970
Technical Sentiment Signal: Sell
Current Market Cap: A$2.97M
For a thorough assessment of ANR stock, go to TipRanks’ Stock Analysis page.